Quince Therapeutics (QNCX) Institutional Ownership $1.58 -0.05 (-3.07%) Closing price 04:00 PM EasternExtended Trading$1.60 +0.02 (+1.58%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Quince Therapeutics (NASDAQ:QNCX)CurrentInstitutional OwnershipPercentage30.75%Number ofInstitutional Buyers(last 12 months)13TotalInstitutional Inflows(last 12 months)$6.37MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$56.65K Get QNCX Insider Trade Alerts Want to know when executives and insiders are buying or selling Quince Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data QNCX Institutional Buying and Selling by Quarter Quince Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Shay Capital LLC150,000$248K0.0%-18.6%0.279% 8/15/2025 Bridgeway Capital Management LLC128,617$212K0.0%+20.9%0.239% 8/14/2025 Nantahala Capital Management LLC2,528,302$4.17M0.2%N/A4.707% 8/12/2025 XTX Topco Ltd22,660$37K0.0%N/A0.042% 8/8/2025 Rockefeller Capital Management L.P.169,554$280K0.0%N/A0.316% 5/14/2025 Ieq Capital LLC806,780$1.07M0.0%N/A1.828% 5/12/2025 Virtu Financial LLC43,332$58K0.0%+48.4%0.098% 4/11/2025 Intellectus Partners LLC53,312$71K0.0%N/A0.121% 2/17/2025 Two Sigma Investments LP30,341$57K0.0%N/A0.069% 2/17/2025 Shay Capital LLC276,799$518K0.1%+60.8%0.629% 2/14/2025 Northern Trust Corp50,524$94K0.0%+48.5%0.115% 2/12/2025 Geode Capital Management LLC375,932$703K0.0%+10.9%0.854% 2/11/2025 Virtu Financial LLC29,204$55K0.0%N/A0.066% 2/5/2025 Anfield Capital Management LLC26,656$50K0.0%N/A0.061% 1/24/2025 Scharf Investments LLC91,061$170K0.0%N/A0.207% 11/16/2024 Geode Capital Management LLC339,125$263K0.0%+24.2%0.784% 8/9/2024 Renaissance Technologies LLC483,902$363K0.0%-7.0%1.120% 1/12/2024 Scharf Investments LLC91,061$96K0.0%N/A0.212% 7/31/2023 Intellectus Partners LLC53,527$81K0.0%N/A0.148% 7/24/2023 BML Capital Management LLC1,411,839$2.13M1.9%N/A3.892% 5/11/2023EPIQ Capital Group LLC958,469$1.50M0.8%-9.3%2.642% 4/20/2023 Hennion & Walsh Asset Management Inc.31,061$48K0.0%N/A0.086% (Data available from 1/1/2016 forward) QNCX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of QNCX shares? During the previous two years, 14 institutional investors and hedge funds held shares of Quince Therapeutics. The most heavily invested institutionals were Nantahala Capital Management LLC ($4.17M), Ieq Capital LLC ($1.07M), Geode Capital Management LLC ($703K), Renaissance Technologies LLC ($363K), Rockefeller Capital Management L.P. ($280K), Shay Capital LLC ($248K), and Bridgeway Capital Management LLC ($212K).Learn more on Quince Therapeutics' institutional investors. What percentage of Quince Therapeutics' stock is owned by institutional investors? 30.75% of Quince Therapeutics' stock is owned by institutional investors. Learn more on QNCX's institutional investor holdings. Which institutional investors have been buying Quince Therapeutics' stock? Of the 13 institutional investors that purchased Quince Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Nantahala Capital Management LLC ($2.53M), Ieq Capital LLC ($806.78K), Scharf Investments LLC ($182.12K), Rockefeller Capital Management L.P. ($169.55K), Shay Capital LLC ($104.62K), Geode Capital Management LLC ($102.98K), and Intellectus Partners LLC ($53.31K). How much institutional buying is happening at Quince Therapeutics? Institutional investors have bought a total of 4,018,292 shares in the last 24 months. This purchase volume represents approximately $6.37M in transactions. Which of Quince Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Quince Therapeutics stock in the last 24 months: Shay Capital LLC ($34.33K). How much institutional selling is happening at Quince Therapeutics? Institutional investors have sold a total of 34,334 shares in the last 24 months. This volume of shares sold represents approximately $56.65K in transactions. Related Companies Zhengye Biotechnology Major Shareholders ADC Therapeutics Major Shareholders Benitec Biopharma Major Shareholders 4D Molecular Therapeutics Major Shareholders Inhibrx Biosciences Major Shareholders Candel Therapeutics Major Shareholders Larimar Therapeutics Major Shareholders Rocket Pharmaceuticals Major Shareholders Amarin Major Shareholders Aldeyra Therapeutics Major Shareholders This page (NASDAQ:QNCX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access